Tetra Bio-Pharma Accelerates Sales Strategy with the Appointment of Denis Courchesne as Vice President, Sales
Tetra Bio-Pharma Accelerates Sales Strategy with the Appointment of Denis Courchesne as Vice President, Sales
OTTAWA, ONTARIO–(Marketwired – April 24, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP) (OTCQB:GRPOF), today announced that it has accelerated its sales strategy by entering into an employment agreement with Denis Courchesne as Vice President, Sales, effective Monday, May 1, 2017.
Mr. Courchesne has over 25 years’ sales and management experience in the retail environment working for various companies such as Evian Spring Water (Danone) and Pfizer Canada.
In the last 15 years, he has been working in both the pharmacy and health food channels where he successfully held positions in Quebec as National Sales Manager. In his previous companies, he rapidly reorganized the sales forces enabling the teams to outperform their sales and profit objectives. Since 2010 Mr. Courchesne has been working as an independent consultant helping various brands in many aspects of their business such as marketing, strategy and goal establishment while enabling them to solidify their presence at store level.
“We are most pleased to welcome Mr. Courchesne to the team as we are focused on building Tetra as a leading bio-pharmaceutical organization,” said Andre Rancourt, CEO of Tetra Bio-Pharma. “Mr. Courchesne has repeatedly demonstrated his skills as a natural leader that will allow Tetra to build our Agro Tek natural health division and drive strong revenue growth for the organization. The great relations he has successfully built over his career specifically in Canadian pharmacies will allow Tetra to accelerate placement of our products and ultimately drive stronger sales moving forward.”
About Tetra Bio Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP) (OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
CONTACT INFORMATION
-
Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(343) 689-0714
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis
Tetra Bio-Pharma & Aphria Announce Plans for the Joint Distribution of Dried Medical Cannabis in the Maritime Provinces & Quebec
Momentum Public Relations
Press Release: April 19, 2017
Tetra Bio-Pharma Inc. (“Tetra”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) and Aphria Inc. (“Aphria”) (TSX:APH) (OTCQB:APHQF), announced plans today for the joint distribution of dried medical cannabis in the maritime provinces and Quebec.
Tetra and Aphria will enter into a joint supply agreement, with Aphria supplying dried medical cannabis under its ACMPR license, and Tetra packaging the product using the manufacturing process developed for its in-progress clinical drug trial for PPP001. The formulation and packaging will be completed by Tetra, under its CDSA dealer’s licence, at its New Brunswick facility. Based on the success of the venture, Tetra and Aphria may expand into other provinces. The venture is preparing to initiate its commercial operations early summer 2017 with revenues commencing in Tetra’s third quarter of 2017 and Aphria’s first quarter of 2018.
“This commercial venture is an important decision for Tetra shareholders as it will start generating revenues this summer which will be invested back into developing PPP001 as a prescription pharmaceutical,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra will be accelerating its manufacturing and quality studies as required by the U.S. and Canadian prescription drug and controlled substance regulations. The investment in this research will be offset by sales revenues generated under the ACMPR.”
“The commercial venture between Tetra and Aphria will enhance Aphria’s brand visibility and distribution of our high-quality medical grade cannabis into the maritime provinces and Quebec, as we look to meet the commercial demand for PPP001,” said Vic Neufeld, CEO of Aphria Inc. “As a leading Canadian licensed producer, it was important for us to work with an organization that shares our focus on pharmaceutical-grade quality assurance and control. Tetra’s emphasis on developing products driven by patient needs and scientific research and development makes them the perfect partner in this important next step for Aphria.”
Tetra and Aphria have invested in the development of its PPP001 drug and will continue to invest to bring PPP001 to market in both Canada and USA as the first prescription drug using dried cannabis. The corporations have developed a high quality dried cannabis product and would like to make it available to physicians under the current ACMPR program. The quality and clinical research studies completed to date would be integrated into a joint Continuing Medical Education program for physicians and pharmacists. Tetra and Aphria have concluded that there is demand for an evidence-based approach in medical cannabis and the two companies intend on using their pharmaceutical approach to help patients. The venture will also be commercializing devices for the inhalation of medical cannabis.
About Tetra Bio-Pharma:
Tetra Bio-Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
About Aphria:
Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada. Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. We are committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders. We are the first public licenced producer to report positive cash flow from operations and the first to report positive earnings in consecutive quarters. For more information, visit www.Aphria.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
- Published in Bio technology, Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma Announces the Opening of a New Brunswick Office for Manufacturing & Sales Activities
Tetra Bio-Pharma Announces the Opening of a New Brunswick Office for Manufacturing & Sales Activities
Momentum Public Relations
Press Release: April 12, 2017
OTTAWA, ONTARIO–(Marketwired – April 12, 2017) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTCQB:GRPOF) announced today it has opened an office in Moncton, New Brunswick for its manufacturing and sales activities. New Brunswick is becoming the hub for the Canadian Cannabis industry.
Tetra is preparing to commercialize several retail products later this year with expected revenues to be generated for the corporation in the fourth quarter. Tetra has already initiated the process to manufacture the first products that act on the cannabinoid system that will be commercialized later this year for sale in Canada and the USA. The Company also intends on commercializing devices (e.g., pipes) for the consumption of medical marijuana in 2017. The Tetra office in Moncton will be responsible to oversee the timely production and launch of the products as well as adhering to the corporation’s budgets.
Tetra has initiated its Phase I clinical trial in March 2017 after manufacturing the PPP001 cannabis drug product at the Ford Pharma contract manufacturing facility in Moncton, New Brunswick. This contract facility developed the proprietary process and equipment required to produce PPP001 pellets and packaging operations. Tetra is also using the contract services of RPC, a New Brunswick provincial crown corporation, to perform its quality control studies to assure that PPP001 conforms to its drug product specifications and quality requirements of a prescription drug.
“We are pleased to announce the opening of a new office in New Brunswick which has become one of the leading provinces in Canada to support the cannabis industry,” said Andre Rancourt, CEO of Tetra Bio-Pharma Inc. “Tetra will manufacture our PPP001 prescription drug as well as additional scheduled products later this year. We are advancing our projects forward which are on time and on budget, a key priority for the Tetra team. We are now one-step closer towards our goal of commercialization in bringing our innovative cannabis based products to market.”
“We acted quickly to prepare for the development of this industry in New Brunswick,” said Stephen Lund, CEO of Opportunities NB. “The addition of Tetra Bio-Pharma to the province is welcomed news. We have the research, education and production facilities in place for companies to be successful in this rapidly growing industry.”
According to Dr. Guy Chamberland, CSO at Tetra Bio-Pharma Inc., “The use of the facility in Moncton allows Tetra to manufacture the PPP001 drug product for the clinical trial according to the corporation’s timelines and budget. The RPC research and technology organization provides Tetra with the high-level expertise required for assessing the quality aspects of PPP001 while keeping the costs associated with these activities within budget due to RPC not-for-profit status. I can report that the Phase 1 trial is advancing on schedule and according to the corporation’s plans we expect to complete the Phase Ia portion of the study by mid-May. The results of the Phase Ia will provide TBP with a strategic understanding of the commercial potential of marijuana products and allow the corporation to complete its Phase II and III trial plans.”
About Tetra Bio Pharma:
Tetra Bio Pharma is a multi subsidiary publicly traded company (CSE:TBP)(CSE:TBP.CN)(OTCQX:GRPOF) engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant based elements.
Tetra Bio Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators physicians and insurance companies. More information is available about the company at: www.tetrabiopharma.com.
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
CONTACT INFORMATION
-
Tetra Bio-Pharma Inc.
Edward Miller
Vice President, IR & Corporate Communications
edward@tetrabiopharma.com
(343) 689-0714
- Published in Life Sciences, Medical Marijuana, News Home, Tetra Bio Pharma
Tetra Bio-Pharma Inc. Completes Pre-IND Meeting with Food and Drug Administration on PPP001
Tetra Bio-Pharma Inc. Completes Pre-IND Meeting with Food and Drug Administration on PPP001
OTTAWA, ONTARIO–(Marketwired – Jan. 30, 2017) – PhytoPain Pharma Inc. (“PPP”), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company”) (CSE:TBP)(CSE:TBP.CN)(OTC PINK:GRPOF), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain and other medical conditions announces that it has completed its pre-IND meeting with the USA Food and Drug Administration (“FDA”) for its PPP001 dried cannabis drug product. The meeting was held in January 2017 with the Division of Anesthesia, Analgesia, and Addiction Products (“DAAAP”), Center for Drug Evaluation and Research (“CDER”).
The FDA provided all the necessary guidance on the design of the Phase I trial in healthy volunteers and the overall product development program, including quality, nonclinical and the medical device, and on marketing requirements. Dr. Chamberland, M.Sc., Ph.D., Chief Scientific Officer and Regulatory Affairs, commented “We could not be more pleased, as the FDA guidance gave us a clear path to progress from early to late phase clinical development. Adhering to the US FDA regulations is part of Tetra Bio-Pharma’s dedication to the commercialization of Cannabis as a prescription controlled drug and the corporations plan to seek reimbursement by insurers for patients.”
The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.
Forward-looking statements
Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.
Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225
Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 689-0714
© 2017 Canjex Publishing Ltd. All rights reserved.
- Published in Medical Marijuana, News Home, Tetra Bio Pharma
Medical Cannabis: an Effective Tool to Manage Severe Pain
Medical Cannabis: an Effective Tool to Manage Severe Pain
Many people have heard about medical cannabis or medical marijuana. This natural remedy can be used to treat inflammation in the body, as well as symptoms of a number of other medical conditions. Do you know why it is so effective as a means to manage severe pain?
About Cannabis: An Overview
Cannabis is a plant that grows wild in many parts of the world. Marijuana refers to the flowers (buds) and leaves of the female plant, which are cured (dried). Hemp is cannabis that is grown for its fibre. It’s used to make a variety of products, including rope, paper and clothing.
Medical marijuana is specifically bred to have larger buds than the wild variety. It also has higher levels of the compounds that affect the mind. These active pharmacological components of cannabis are effective in treating pain and other medical conditions in the human body because they are similar to a system that already exists in the human body. It is called the Endocannabinoid System (ECS).
Endocannabinoid System
The body’s ECS is controlled by chemicals that it produces, which are known as endocannabinoids. These endocannabinoids are the chemicals that are responsible for keeping a number of the body’s functions in balance, such as appetite, sleep and immune function. They also regulate pain. When the body is stressed in some manner, these specialized chemicals go to work and attempt to deal with the issue.
When someone ingests cannabis, it mimics the function of these types of chemicals that the body produces naturally, resulting in relief from pain. Cannabis also lowers inflammation by working with the body’s endocannabinoid system.
Active Ingredients in Cannabis
Cannabis is a type of plant that contains more than 400 active chemicals. The active components found in cannabis are referred to as cannabinoids. There are more than 100 different cannabinoids present in cannabis. The most common one is delta-9 tetrahydrocannabinol, or THC. This is the ingredient that produces the feeling of being “high” that recreational users experience.
CBD is another cannabinoid contained in cannabis. Unlike THC, it doesn’t give users a “high.” Instead it helps to dampen the effects of THC (euphoria and lethargy).
Heath Benefits of THC and CBD
THC and CBD offer a number of health benefits when ingested. THC is a strong pain reliever and anti-inflammatory, having many more powerful properties than both Aspirin and hydrocortisone. THC has anti-spasmodic and muscle relaxant qualities. It is also a powerful antioxidant.
CBD is second most powerful cannabinoid contained cannabis. It is the most common one found in hemp plants. CBD is known for its ability to relieve symptoms of anxiety and depression, as well as tachycardia (rapid heartbeat). It has also been used to control some forms of epilepsy, can help to regulate blood pressure and reduce nausea.
CBD-rich cannabis strains provides powerful therapeutic benefits without giving users the sense of euphoria or lethargy that ones with higher levels of THC produce. Medical cannabis would be made up of these types of specially-bred strains. The medical marijuana available from authorized distributors is not the same product that the public pictures being available from street vendors.
The plant strains are selected and bred to provide the best results for patients. In the case of a medical treatment strain, the marijuana would likely contain a balance of THC and CBD that would balance its pain-relief, anti-inflammatory and other benefits with the risk of producing a feeling of euphoria and lethargy. Patients who use marijuana for medical purposes want to be able to remain functional while achieving pain relief and other benefits.
All cannabinoids, including THC and CBD, must be heated in order to convert their acids into active ingredients. For this reason, smoking is an effective way of ingesting the product. It’s the most expedient way to get the THC and CBD into the bloodstream. The interior of the lungs’ surfaces are covered with millions of alveoli (tiny air sacs where gas exchange occurs). These air sacs have a surface area much greater than the skin, making it easy for the chemicals in the medical marijuana to enter the body, usually within seconds after ingestion. Vaporizers, which heat the cannabis to a level in order to vaporize the active ingredients without burning, may also be used to ingest medical cannabis.
Smokable Bio Cannabis Pharmaceutical from Tetra Bio-Pharma
Tetra Bio-Pharma is a publicly-traded company (CSE:TBP) that is actively engaged in developing bio pharmaceuticals and natural health products. The company works with cannabis and other medicinally-based plant elements as the basis for developing its products. One of the products Tetra Bio-Pharma is currently developing a smokable bio-cannabis pharmaceutical. For more information on Tetra Bio-Pharma’s products and clinical trials check out this link to their site: http://tetrabiopharma.com/products/
- Published in Blog, Medical Marijuana, Tetra Bio Pharma
About the Vitaleaf Community
Vita Leaf
The vital link between alternative medicine patients, prescribers and distributors. Currently Vitaleaf is producing an online ebook that includes various information on medicinal herbs as well as interviews with doctors and patients who are currently using medicinal herbs to treat various ailments and diseases.
Invictus MD Strategies (IMH:CSE) currently owns 100{92d3d6fd85a76c012ea375328005e518e768e12ace6b1722b71965c2a02ea7ce} of Vitaleaf.
Invictus – Investment portfolio and cash flow generation
With a diverse portfolio, INVICTUSMD engages in long-lasting, strategic investment opportunities, which will promote durable growth and shareholder value. The companies targeted for investment must demonstrate specific traits including proven brand recognition, sound management, compelling market that will support growth, sustainable and differentiated advantage over competitors.
You can find below a brief description of the 6 verticals developed by INVICTUSMD, from which 3 are cash flow positive.
- Published in Blog, Medical Marijuana
- 1
- 2